相关实验视频

Updated: Jul 25, 2025

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

一个简单的语言总结的结果,从GARNET研究的 dostarlimab在患有子宫内膜癌的患者

Ana Oaknin¹, Lucy Gilbert², Anna V Tinker³

¹Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital.

Future oncology (London, England)

|June 29, 2023

概括

多斯塔利马布 (JEMPERLI) 在子宫内膜癌患者中显示出显著的瘤减少. 这种免疫疗法为那些患有晚期或复发性疾病的人提供了可管理的副作用和潜在的长期益处.

科学领域:

在瘤学瘤学.
临床药理学临床药理学
免疫治疗是一种免疫疗法.

背景情况:

子宫内膜癌,特别是晚期或复发的形式,具有有限的治疗选择.
多斯塔利马布是一种针对特定癌症途径的试验性免疫治疗药物.

研究的目的:

评估在患有子宫内膜癌的患者中提供利马布的安全性和疗效.
为了确定提供达利利马布治疗的最佳剂量和施用策略.

主要方法:

GARNET研究是一项正在进行的第一阶段临床试验.
患者接受了delarlimab,在中间分析中评估了安全性,耐受性和疗效.

主要成果:

在一组子宫内膜癌患者中,多斯塔利马布治疗导致瘤大小的减少.
观察到的副作用一般是可控的,严重不良事件的发生率很低.

结论:

该研究的GARNET研究结果支持批准提供利利马布用于特定的子宫内膜癌指示.
杜斯塔利马布作为一种有价值的治疗选择显示出希望,可能为患有晚期或复发性子宫内膜癌的患者提供持久的反应.

关键词:

宫内膜癌宫内膜癌是什么?妇科癌症妇科癌症免疫治疗是一种免疫疗法.简单的语言总结

更多相关视频

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...